Board of Directors
Chairman & Co-Founder
Bob G. Gower, former President and CEO of Carbon Nanotechnologies Inc., has more than 40 years of experience in the chemical industry, 30 of which were in operational and managerial roles for such companies as Atlantic Richfield, ARCO Chemical, and Lyondell Petrochemical Company. Gower became president of Lyondell when it was formed in 1985 and led its transformation from an unprofitable company to one recognized as one of the 100 best manufacturing companies in the world. Together with Dr. Richard Smalley, Dr. Gower founded Carbon Nanotechnologies, Inc. (CNI) in 2000 developing fullerene carbon nanotubes for multiple applications. CNI was acquired by Unidym in 2007. Dr. Gower founded Ensysce Biosciences Inc. in early 2008 for the specific focus of using carbon nanotubes in therapeutic areas. Bob received his PhD from the University of Minnesota.
William H.C. Chang
Director and Co-Founder
William H.C. Chang is the Chairman of Westlake International Group, a privately held, diversified investment company with operations in the United States, China, Japan and India. Its investments span private and public equities, including venture capital, professional sports, media and entertainment, emerging technologies, life sciences and real estate. He is also the Co-Owner and on the Executive Committee of the San Francisco Giants Baseball Club, Co-Owner and General Partner of D.C. United, and Chairman of the Executive Committee of U.S.A. Rugby. Chang's associations and affiliations include: the Asian Business League (Founding Chairman); California International Relations Foundation (Director); Chinese American Association of Commerce (Founder); City Club of San Francisco (Founding Governor); Harvard University (Asia Center and Committee on University Resources); and World President's Organization. Chang has a bachelor's degree in Economics from Harvard College, Cambridge, Massachusetts.
D. Lynn Kirkpatrick, PhD.
Dr. Kirkpatrick has focused her entire career on cancer drug discovery and development. Former Professor of Chemistry and Biochemistry at the University of Regina, Canada, she has co-founded two start up companies and successfully brought three novel cancer drug candidates into human clinical trails. Following the acquisition of her first company, by Biomira Inc., (Oncothyreon) in 2006, Dr. Kirkpatrick took the role as the Chief Scientific Officer of the merged company. She became President and CEO of Ensysce Biosciences Inc. in January 2009. Dr. Kirkpatrick received her PhD from the University of Saskatchewan and completed a post-doctoral fellowship at Yale University School of Medicine. She has published extensively in the area of targeted cancer drug discovery and development and holds numerous patents for novel targeted cancer drugs.